Intervacc is trading at €0.08, down -13.43%, with no confirmed catalyst identified.
- No clear company-specific announcement was identified for August 12, 2026.
- The latest surfaced catalyst was Intervacc’s July 30 EMA filing seeking 12-month Strangvac immunity; its next earnings report is scheduled for August 20, 2026.
- Broader markets were essentially flat, and the move currently appears idiosyncratic or liquidity-driven, without a confirmed catalyst.